The PennZone

PHILADELPHIA, May 4, 2021 /PRNewswire/ -- ExtriCARE USA, a national medical device company specializing in negative pressure wound therapy (NPWT) distribution, is excited to introduce hybrid technology to the wound care market.

The company firmly believes NPWT is still in its infancy stage. There is a tremendous opportunity for growth and innovation because this niche market is evolving. ExtriCARE USA recognizes the potential and is proactively investing in the future of NPWT, which will lead to more positive results for medical equipment providers, clinicians and patients.

ExtriCARE USA has developed a new concept to take the NPWT evolution to the next stage. They plan to positively disrupt the market with hybrid technology that brings versatility to the next level. This concept, coined as hNPWT, will provide patients with a continuum of care necessary to heal wounds more efficiently.

More on The PennZone

• Slotozilla Launches New Report on How AI Is Reshaping Careers and Society
• OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
• Explosive Growth in U.S. Cryptocurrency Cloud Mining Sets The Stage for New Platform Launch with Daily Rewards in a Transparent Revenue-Share Model
• Qtex Cierra Ronda de $7 Millones para Estandarizar la Banca Transfronteriza en los Mercados Emergentes de Latinoamérica
• Ring in the Season with Free Holiday Jazz from The Jazz Sanctuary

Currently, there are two primary applications of NPWT—traditional (tNPWT) and single-use (sNPWT). ExtriCARE USA understands wound healing is not a uniform approach. Through hybrid technology (hNPWT), clinicians can tailor the application based on the patients' distinct needs.

ExtriCARE USA's hybrid model will allow clinicians to be more efficient by simplifying the NPWT process. This hybrid system allows for one pump to utilize both silicon incisional and traditional foam dressing kits. Clinicians will confidently apply which approach will be best suited for the patient.

"Hybrid technology is the future of NPWT," said Peter Mason, President. "Our new product line will be the most adaptable NPWT system in the wound care industry."

When developing new medical devices, it's essential to consider the wide variety of preferences and benefits to all approaches. ExtriCARE USA's hybrid model significantly considers this by giving clinicians the freedom to make their own decisions and work around the patient's needs.

More on The PennZone

• America's Most Festive Garages Wanted for Garage.com's 2025 Holiday Contest
• FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
• BEC Technologies Expands MX-220 5G Industrial Router Series for Edge Connectivity
• "Latino Leaders Speak: Personal Stories of Struggle and Triumph, Volume II" Documents the Truth About Latino Excellence and Impact on American Society
• Broadway Smile Boutique Unveils Modern Website for Enhanced Patient Experience

ExtriCARE USA is working closely with manufacturer Alleva Medical to design the new product line to bring this hybrid concept to life.

For press inquiries or more information, please contact Binh Nguyen at 717-389-2928 or [email protected].

About ExtriCARE USA:
ExtriCARE USA is a national medical device distribution company specializing in negative pressure wound therapy (NPWT). Our products save clinicians time and benefit patients by introducing solutions that are mobile and provide a more flexible therapy. To learn more, visit www.extricareusa.com.

SOURCE ExtriCARE USA

Related Links

https://extricareusa.com

---

Show All News | Report Violation